PetCaseFinder

Peer-reviewed veterinary case report

Biomarker to tell metastatic from non-metastatic oral melanoma in dogs

By Hasan, Md Nazmul et al.·Published in The veterinary quarterly·2024·Joint Graduate School of Veterinary Medicine, Japan·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Hypoxia-related Y RNA fragments as a novel potential biomarker for distinguishing metastatic oral melanoma from non-metastatic oral melanoma in dogs.

Species:
dog

Plain-English summary

A study found that dogs with metastatic oral melanoma (a type of mouth cancer) had lower levels of a specific RNA fragment called Y RNA compared to those with non-metastatic melanoma. This difference was observed in various samples, including tumor tissue and blood. The researchers suggest that measuring Y RNA levels could help veterinarians distinguish between metastatic and non-metastatic cases, which is important for treatment decisions. However, more research is needed to fully understand how Y RNA behaves in these conditions and its role in cancer progression.

People also search for: dog oral melanoma treatment · metastatic melanoma in dogs · Y RNA biomarker for dogs

Abstract

Hypoxia may promote tumor progression, and hypoxically altered noncoding RNA (ncRNA) expression may play a role in metastasis. Canine oral melanoma (COM) frequently metastasizes, and ncRNA expression under hypoxia may be clinically significant. We aimed to elucidate ncRNA fragments whose expression is altered by hypoxia in COM-derived primary KMeC and metastatic LMeC cell lines using next-generation sequencing to validate these results in qRT-PCR, and then compare expression between metastatic and non-metastatic COM. The NGS analysis and subsequent qRT-PCR validation were performed using hypoxic and normoxic KMeC and LMeC cells, and clinical samples [tumor tissue, plasma, and plasma-derived extracellular vesicles] obtained from dogs with metastatic or non-metastatic melanoma were analyzed with qRT-PCR. Y RNA was significantly decreased in metastatic LMeC cells versus primary KMeC cells in hypoxic and normoxic conditions. The expression of Y RNA was decreased in dogs with metastatic melanoma versus those with non-metastatic melanoma for all clinical sample types, reflecting the pattern found with hypoxia. Receiver operating characteristic analysis demonstrated that Y RNA level is a promising biomarker for discriminating metastatic from non-metastatic melanoma in plasma [area under the curve (AUC)&#xa0;=&#xa0;0.993,&#x2009;<&#x2009;0.0001] and plasma-derived extracellular vesicles (AUC = 0.981,&#x2009;=&#x2009;0.0002). Overall, Y RNA may be more resistant to hypoxic stress in the metastatic than the non-metastatic state for COM. However, further investigation is required to elucidate the biological functions of Y RNA under hypoxic conditions.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38288969/